First patient enrolled in new study where the Diamyd® diabetes vaccine is administered directly into lymph nodes - DIAGNODE has started

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that the first patient has been enrolled in the DIAGNODE study. In the study a new way to administer the Diamyd® diabetes vaccine is tested, directly into inguinal lymph nodes.DIAGNODE is the first study of its kind, where a low dose of Diamyd® is administered directly into lymph nodes in combination with treatment with vitamin D. The concept, for which Diamyd Medical has submitted a patent application, can be compared to the development in allergy therapy, where the administration of allergen into lymph nodes has